ASINEX is interested in research, development and commercialization relationships with pharmaceutical and biotechnology companies.



ASINEX has mastered its Compound-to-Target™ platform that facilitates translation of innovative small molecule and macrocyclic chemistry into pre-clinical leads focusing on specific oncogenic pathways:



     ・ Apoptotic pathway


     ・ Cyclin-dependent kinase pathways


     ・ Wnt/β-catenin signaling pathway 



In addition to oncology, the platform provides valuable starting points for antibacterial R&D.



For more information, please contact us.